Company news

Vir Biotechnology, Inc. news in 2026

Vir Biotechnology, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call

November 5, 2026

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results

November 4, 2026

Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference

November 2, 2026

Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors

October 28, 2026

Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results

October 21, 2026

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

October 14, 2026

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

October 8, 2026

Vir Biotechnology Appoints David Liu as Chief Medical Officer

October 7, 2026

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026

October 5, 2026

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

October 1, 2026

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

August 31, 2026

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 5, 2026

Vir Biotechnology Announces Chief Financial Officer Transition

July 24, 2026

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

July 22, 2026

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

June 10, 2026

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

May 18, 2026

Sotrovimab (Xevudy: Vir Biotechnology, GlaxoSmithKline) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

May 11, 2026

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 6, 2026

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

May 5, 2026

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

April 23, 2026

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

April 15, 2026

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

April 12, 2026

Vir Biotechnology to Participate in Upcoming Investor Conferences

February 25, 2026

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

February 25, 2026

Vir Biotechnology Announces Proposed Public Offering of Common Stock

February 24, 2026

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

February 23, 2026

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

February 22, 2026

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

February 22, 2026

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

February 9, 2026

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

January 11, 2026

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026